The impact of osteopontin promoter polymorphisms on the risk of calcium urolithiasis

Lee, 2002, Epidemiological studies on the prevalence of upper urinary calculi in Taiwan, Urol Int, 68, 172, 10.1159/000048445 Pak, 1998, Kidney stones, Lancet, 351, 1797, 10.1016/S0140-6736(98)01295-1 Lewandowski, 2004, Idiopathic calcium oxalate urolithiasis: risk factors and conservative treatment, Clin Chim Acta, 345, 17, 10.1016/j.cccn.2004.03.009 Chou, 2007, Urinary stone analysis of 1,000 patients in southern Taiwan, Kaohsiung J Med Sci, 23, 63, 10.1016/S1607-551X(09)70376-6 Basavaraj, 2007, The role of urinary kidney stone inhibitors and promotors in the pathogenesis of calcium containing renal stones, EAU-EBU Update Series, 5, 126, 10.1016/j.eeus.2007.03.002 Vezzoli, 2008, Update on primary hypercalciuria from a genetic perspective, J Urol, 179, 1676, 10.1016/j.juro.2008.01.011 Mazzali, 2002, Osteopontin—a molecule for all seasons, QJM, 95, 3, 10.1093/qjmed/95.1.3 Watts, 2005, Idiopathic urinary stone disease: possible polygenic aetiological factors, QJM, 98, 241, 10.1093/qjmed/hci041 Shiraga, 1992, Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily, Proc Natl Acad Sci U S A, 89, 426, 10.1073/pnas.89.1.426 Worcester, 1995, Osteopontin inhibits nucleation of calcium oxalate crystals, Ann N Y Acad Sci, 760, 375, 10.1111/j.1749-6632.1995.tb44661.x Lieske, 1995, Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions, Am J Physiol, 268, F604 Wesson, 1998, Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules, Kidney Int, 53, 952, 10.1111/j.1523-1755.1998.00839.x Giacopelli, 2004, Polymorphisms in the osteopontin promoter affect its transcriptional activity, Physiol Genomics, 20, 87, 10.1152/physiolgenomics.00138.2004 Hummelshoj, 2006, A functional polymorphism in the Eta-1 promoter is associated with allele specific binding to the transcription factor Sp1 and elevated gene expression, Mol Immunol, 43, 980, 10.1016/j.molimm.2005.05.012 Hendig, 2007, SPP1 promoter polymorphisms: identification of the first modifier gene for pseudoxanthoma elasticum, Clin Chem, 53, 829, 10.1373/clinchem.2006.083675 Brenner, 2006, Cytokine polymorphisms associated with carotid intima-media thickness in stroke patients, Stroke, 37, 1691, 10.1161/01.STR.0000226565.76113.6c Naito, 2005, SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C, J Gastroenterol, 40, 381, 10.1007/s00535-005-1558-3 Liu, 2007, Association of vitamin D receptor (Fok-I) polymorphism with the clinical presentation of calcium urolithiasis, BJU Int, 99, 1534, 10.1111/j.1464-410X.2007.06792.x Liu, 2009, The impact of cigarette smoking, alcohol drinking and betel quid chewing on the risk of calcium urolithiasis, Ann Epidemiol, 19, 539, 10.1016/j.annepidem.2009.02.006 Barrett, 2005, Haploview: analysis and visualization of LD and haplotype maps, Bioinformatics, 21, 263, 10.1093/bioinformatics/bth457 Tzeng, 2006, Regression-based association analysis with clustered haplotypes through use of genotypes, Am J Hum Genet, 78, 231, 10.1086/500025 Mo, 2007, Renal calcinosis and stone formation in mice lacking osteopontin, Tamm–Horsfall protein, or both, Am J Physiol Renal Physiol, 293, F1935, 10.1152/ajprenal.00383.2007 Wesson, 2003, Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules, J Am Soc Nephrol, 14, 139, 10.1097/01.ASN.0000040593.93815.9D Yasui, 1999, Quantification of osteopontin in the urine of healthy and stone-forming men, Urol Res, 27, 225, 10.1007/s002400050114 Huang, 2003, Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones, Urology, 62, 1123, 10.1016/S0090-4295(03)00764-7 Lieske, 1997, Renal cell osteopontin production is stimulated by calcium oxalate monohydrate crystals, Kidney Int, 51, 679, 10.1038/ki.1997.98 Khan, 2006, Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-l-proline, Kidney Int, 70, 914, 10.1038/sj.ki.5001699 Batinic, 2000, Value of the urinary stone promoters/inhibitors ratios in the estimation of the risk of urolithiasis, J Chem Inf Comput Sci, 40, 607, 10.1021/ci990076i Gao, 2005, A polymorphism of the osteopontin gene is related to urinary calcium stones, J Urol, 174, 1472, 10.1097/01.ju.0000173012.28341.c3 Gao, 2007, Association of osteopontin gene haplotypes with nephrolithiasis, Kidney Int, 72, 592, 10.1038/sj.ki.5002345 Tsai, 1991, Comparison between spot urine and overnight urine in the estimation of 24-hour excretion of urine protein, sodium and kallikrein, J Formos Med Assoc, 90, 755 Cirillo, 1993, Can overnight urine replace 24-hour urine collection to measure urinary calcium in epidemiologic studies?, Miner Electrolyte Metab, 19, 385 He, 1993, Agreement between overnight and 24-hour urinary cation excretions in southern Chinese men, Am J Epidemiol, 137, 1212, 10.1093/oxfordjournals.aje.a116623